Proscar and Coronary arterial stent insertion - a phase IV clinical study of FDA data

Summary:

Coronary arterial stent insertion is reported as a side effect among people who take Proscar (finasteride), especially for people who are male, 60+ old, have been taking the drug for 5 - 10 years also take Aspirin, and have Osteoporosis.

The phase IV clinical study analyzes which people have Coronary arterial stent insertion when taking Proscar. It is created by eHealthMe based on reports of 13,025 people who have side effects when taking Proscar from the FDA, and is updated regularly.

What is Proscar?

Proscar has active ingredients of finasteride. It is often used in prostate examination abnormal. eHealthMe is studying from 13,379 Proscar users. Check the latest studies of Proscar.

What is Coronary arterial stent insertion?

Coronary arterial stent insertion is found to be associated with 370 drugs and 489 conditions by eHealthMe. Check the latest studies of Coronary arterial stent insertion.

On Jul, 12, 2026

13,025 people reported to have side effects when taking Proscar.
Among them, 29 people (0.22%) have Coronary arterial stent insertion.

Could Proscar cause Coronary arterial stent insertion?

Among these 29 people:

How long have people been on Proscar when they have Coronary arterial stent insertion? *

What is the gender of people who have Coronary arterial stent insertion when taking Proscar? *

female: 0.0 %
male: 100 %

What is the age of people who have Coronary arterial stent insertion when taking Proscar? *

What are other drugs people take besides Proscar? *

What are other side effects people have besides Coronary arterial stent insertion? *

Gynecomastia (enlargement of the gland tissue of the male breast): 17 people, 58.62%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 16 people, 55.17%
Anaemia (lack of blood): 16 people, 55.17%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 15 people, 51.72%
Bone Scan Abnormal: 15 people, 51.72%
Pain: 15 people, 51.72%
Parathyroid Tumor Benign: 15 people, 51.72%
Bone Disorder: 15 people, 51.72%
Blood Parathyroid Hormone Increased: 15 people, 51.72%
Colonic Polyp (extra part of colon tissue grow in intestine): 15 people, 51.72%

What are the existing conditions these people have? *

Prostate Cancer: 15 people, 51.72%
Osteoporosis (bones weak and more likely to break): 15 people, 51.72%
High Blood Cholesterol: 3 people, 10.34%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (long lasting infection of nerves outside brain and spinal cord): 3 people, 10.34%
Type 2 Diabetes: 1 person, 3.45%
Stress And Anxiety: 1 person, 3.45%
Prostatic Specific Antigen Increased: 1 person, 3.45%
Neuropathic Pain (pain due to nerve inflammation and damage): 1 person, 3.45%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 1 person, 3.45%
High Blood Pressure: 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Proscar and have Coronary arterial stent insertion?

- Check whether Coronary arterial stent insertion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Proscar:

Proscar (13,379 reports)

Browse all side effects of Proscar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Coronary arterial stent insertion:

Coronary arterial stent insertion (370 drugs)

Browse all the conditions that are associated with Coronary arterial stent insertion:

Coronary arterial stent insertion (489 conditions)

Related publications that referenced our studies

Fouda AM, Bazeed AM, "Hematuria and Hematospermia Associated with the Use of Finasteride for the Treatment of Androgenic Alopecia: A Case Report", Drug Safety-Case Reports, 2017 Dec .
Fouda AM, Bazeed AM, "Hematuria and Hematospermia Associated with the Use of Finasteride for the Treatment of Androgenic Alopecia: A Case Report", Drug Safety-Case Reports, 2017 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on finasteride (the active ingredients of Proscar) and Proscar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.